Thomas Fischer - Bayer Aktiengesellscha Member of the Supervisory Board
BAYZF Stock | USD 28.97 0.31 1.06% |
Executive
Dr. Thomas Fischer was Member of the Supervisory Board and Employee Representative of Bayer Aktiengesellschaft since October 1, 2005. Additionally, he acts as Member of the Audit Committee of the Company since 2005.
Age | 60 |
Tenure | 19 years |
Phone | 49 214 30 1 |
Web | https://www.bayer.com |
Bayer Aktiengesellscha Management Efficiency
The company has return on total asset (ROA) of 0.0576 % which means that it generated a profit of $0.0576 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.13 %, meaning that it generated $0.13 on every $100 dollars invested by stockholders. Bayer Aktiengesellscha's management efficiency ratios could be used to measure how well Bayer Aktiengesellscha manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Klaus Moosmayer | Novartis AG ADR | 56 | |
Sophie KornowskiBonnet | Roche Holding Ltd | 54 | |
Susanne Fiedler | Organon Co | 56 | |
Natalie Bickford | Sanofi ADR | 54 | |
James Sabry | Roche Holding Ltd | 59 | |
Daniel Karp | Organon Co | 46 | |
Eva Tubau | Grifols SA ADR | N/A | |
Richard Francis | Novartis AG ADR | 50 | |
Mikael MD | Pfizer Inc | 66 | |
Susan ONeal | Organon Co | N/A | |
Pierre Chancel | Sanofi ADR | 67 | |
Verena Briner | Novartis AG ADR | 64 | |
Joseph Morrissey | Organon Co | 59 | |
George Gunn | Novartis AG ADR | 63 | |
Alan Hippe | Roche Holding Ltd | 56 | |
Rebecca Edwards | Organon Co | N/A | |
John Reed | Roche Holding Ltd | 59 | |
Karenann Terrell | GlaxoSmithKline PLC ADR | 58 | |
Susan MD | AstraZeneca PLC ADR | 58 | |
Roy Papatheodorou | Sanofi ADR | 46 | |
Robert Weltevreden | Novartis AG ADR | 52 |
Management Performance
Return On Equity | 0.13 | |||
Return On Asset | 0.0576 |
Bayer Aktiengesellschaft Leadership Team
Elected by the shareholders, the Bayer Aktiengesellscha's board of directors comprises two types of representatives: Bayer Aktiengesellscha inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bayer. The board's role is to monitor Bayer Aktiengesellscha's management team and ensure that shareholders' interests are well served. Bayer Aktiengesellscha's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bayer Aktiengesellscha's outside directors are responsible for providing unbiased perspectives on the board's policies.
Oliver Maier, Head Relations | ||
Heiko Schipper, Member of the Management Board, Head of the Consumer Health Division | ||
Thomas Fischer, Member of the Supervisory Board | ||
Marijn Dekkers, Chairman of Management Board and CEO | ||
Helmut Panke, Member of the Supervisory Board | ||
Reiner Hoffmann, Member of the Supervisory Board | ||
Sue Rataj, Member of the Supervisory Board | ||
Petra ReinboldKnape, Member of the Supervisory Board | ||
Dieter Weinand, Member of the Management Board and Head of the Pharmaceuticals Division, North America Region | ||
Werner Baumann, Chief Strategy and Portfolio Officer and Member of Management Board | ||
Sarena Lin, Labor Officer | ||
Simone BagelTrah, Member of the Supervisory Board | ||
Michael SchmidtKiessling, Member of the Supervisory Board | ||
ErnstLudwig Winnacker, Member of the Supervisory Board | ||
Colleen Goggins, Member of the Supervisory Board | ||
Heinz Webers, Member of the Supervisory Board | ||
Johanna Faber, Member of the Supervisory Board | ||
Frank Loellgen, Member of the Supervisory Board | ||
Andre Broich, Member of the Supervisory Board | ||
Liam Condon, Member of Management Board and CEO of Bayer Cropscience | ||
Rodrigo Santos, Member Division | ||
Patrick Thomas, CEO, Bayer MaterialScience | ||
Yueksel Karaaslan, Member of the Supervisory Board | ||
Erica Mann, Member of the Management Board, Head of the Consumer Health Division | ||
Norbert Bischofberger, Member of the Supervisory Board | ||
Hartmut Klusik, Member of the Management Board, Director of Human Resources, Technology & Sustainability | ||
Michael Koenig, Member of the Management Board responsible for Human Resources | ||
Thomas Win, Vice Chairman of the Supervisory Board | ||
Jennifer Brendelto, Vice President - Communications of the Consumer Health Division | ||
Heike Hausfeld, Member of the Supervisory Board | ||
Peter Hausmann, Member of the Supervisory Board | ||
Detlef Rennings, Member of the Supervisory Board | ||
Werner Wenning, Chairman of the Supervisory Board | ||
Michael Preuss, Gov Communications | ||
Kemal Malik, Member of Management Board, Chief Medical Officer of Bayer Healthcare and Head of Global Devel. - Bayer Healthcare | ||
Petra Kronen, Member of the Supervisory Board | ||
Oliver Zuehlke, Member of the Supervisory Board | ||
Thomas Elsner, Member of the Supervisory Board | ||
Alexander Rosar, Head of Investor Relations | ||
Wolfgang Nickl, CFO, Member of the Management Board | ||
Paul Achleitner, Member of the Supervisory Board | ||
Klaus Sturany, Independent Member of the Supervisory Board | ||
Stefan Oelrich, Member of the Management Board, Head of the Pharmaceuticals Division | ||
Thomas Ebeling, Member of the Supervisory Board | ||
Johannes Dietsch, CFO and Member of Management Board | ||
Gabriel Harnier, Patents Law | ||
Norbert Winkeljohann, Independent Member of the Supervisory Board | ||
Clemens Boersig, Member of the Supervisory Board | ||
Juergen Beunink, Interim Head of Investor Relations | ||
Otmar Wiestler, Member of the Supervisory Board | ||
Sabine Schaab, Member of the Supervisory Board | ||
BerndPeter Bier, Head Taxes | ||
Wolfgang Plischke, Member of the Supervisory Board |
Bayer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bayer Aktiengesellscha a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.13 | |||
Return On Asset | 0.0576 | |||
Profit Margin | 0.09 % | |||
Operating Margin | 0.23 % | |||
Current Valuation | 87.41 B | |||
Shares Outstanding | 982.42 M | |||
Shares Owned By Institutions | 47.11 % | |||
Price To Earning | 321.83 X | |||
Price To Book | 1.36 X | |||
Price To Sales | 1.06 X |
Pair Trading with Bayer Aktiengesellscha
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bayer Aktiengesellscha position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bayer Aktiengesellscha will appreciate offsetting losses from the drop in the long position's value.Moving against Bayer Pink Sheet
0.8 | META | Meta Platforms | PairCorr |
0.76 | KB | KB Financial Group Earnings Call Today | PairCorr |
0.75 | PH | Parker Hannifin Earnings Call This Week | PairCorr |
0.74 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
0.74 | DNSKF | Danske Bank AS | PairCorr |
The ability to find closely correlated positions to Bayer Aktiengesellscha could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bayer Aktiengesellscha when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bayer Aktiengesellscha - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bayer Aktiengesellschaft to buy it.
The correlation of Bayer Aktiengesellscha is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bayer Aktiengesellscha moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bayer Aktiengesellschaft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bayer Aktiengesellscha can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bayer Aktiengesellschaft. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Bayer Aktiengesellschaft information on this page should be used as a complementary analysis to other Bayer Aktiengesellscha's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Bayer Pink Sheet analysis
When running Bayer Aktiengesellscha's price analysis, check to measure Bayer Aktiengesellscha's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bayer Aktiengesellscha is operating at the current time. Most of Bayer Aktiengesellscha's value examination focuses on studying past and present price action to predict the probability of Bayer Aktiengesellscha's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bayer Aktiengesellscha's price. Additionally, you may evaluate how the addition of Bayer Aktiengesellscha to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |